NEUROCRINE BIOSCIENCES INC (11)

Browse by Contract Category

Contracts

First Amendment to Collaboration and License Agreement Dated August 31, 2011 between the Company and Abbott International Luxembourg S.a.r.l (Filed With SEC on May 5, 2021)
License Agreement dated February 9, 2017 between BIAL- Portela & CA, S.A. and the Company (Filed With SEC on May 5, 2021)
Form of Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, and Form of Restricted Stock Unit Award Grant... (Filed With SEC on August 3, 2020)
Description of Common Stock of the Company (Filed With SEC on February 7, 2020)
Third Amendment to Amended and Restated Lease between the Company and Kilroy Realty, L.P. dated August 7, 2019 (Filed With SEC on November 4, 2019)
Collaboration Agreement dated June 15, 2010, by and between Abbott International Luxembourg S.a.r.l. and the Company as amended on August 31, 2011 (Filed With SEC on May 5, 2021)
Collaboration and License Agreement dated March 31, 2015 between Mitsubishi Tanabe Pharma Corporation and the Company (Filed With SEC on May 5, 2021)
Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan (Filed With SEC on August 3, 2020)
Employment Agreement dated November 3, 2014 between the Company and Kyle Gano (Filed With SEC on February 7, 2020)
Amendment No. 1 to Collaboration and License Agreement dated June 14, 2019 between Voyager Therapeutics, Inc. and the Company (Filed With SEC on July 29, 2019)
Employment Agreement dated January 8, 2018 between the Company and Eiry W. Roberts, M.D (Filed With SEC on July 29, 2019)